14 min listen
ATHENA-MONO Trial with Bradley J. Monk
FromIJGC Podcast
ratings:
Length:
43 minutes
Released:
Sep 12, 2022
Format:
Podcast episode
Description
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Professor Bradley J. Monk to discuss the ATHENA-MONO clinical trial. Prof. Monk is an international thought leader and clinical trialist who has developed and advocated for maintenance treatment in newly diagnosed advanced and recurrent ovarian cancer. ATHENA-MONO represents his fifth positive randomized phase 3 trial studying maintenance treatment and adds confidence to this efficacious and tolerable paradigm changing opportunity for all patients regardless of the molecular genotype (allcomers).
Highlights:
- Maintenance therapy is now the global standard of care in patients with advanced or recurrent epithelial ovarian cancer. This can include a PAPP inhibitor, bevacizumab, or the combination.
- Maintenance treatment is efficacious in all molecular subgroups and is tolerable without an impairment in the quality of life.
- Payers acknowledge the value of maintenance treatment as do consensus guidelines.
Highlights:
- Maintenance therapy is now the global standard of care in patients with advanced or recurrent epithelial ovarian cancer. This can include a PAPP inhibitor, bevacizumab, or the combination.
- Maintenance treatment is efficacious in all molecular subgroups and is tolerable without an impairment in the quality of life.
- Payers acknowledge the value of maintenance treatment as do consensus guidelines.
Released:
Sep 12, 2022
Format:
Podcast episode
Titles in the series (100)
The Use of Parp Inhibitors in Advanced Ovarian Cancer with Robert Coleman: In this episode of the IJGC podcast, Editor-in-Ch… by IJGC Podcast